

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 July 2021 (08.07.2021)



(10) International Publication Number
WO 2021/138346 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) G01N 33/68 (2006.01)
C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/067345

(22) International Filing Date:

29 December 2020 (29.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/955,477 31 December 2019 (31.12.2019) US

(71) Applicant: NAVROGEN, INC. [US/US]; 66 Mount Aire Farm Road, Glen Mills, Pennsylvania 19342 (US).

(72) Inventors: NICOLAIDES, Nicholas C.; 66 Mount Aire Farm Road, Glen Mills, Pennsylvania 19342 (US). GRASSO, Luigi; 403 Barbara Lane, Bryn Mawr, Pennsylvania 19010 (US). KLINE, James Bradford; 29 Lenape Drive, Morgantown, Pennsylvania 19543 (US).


(74) Agent: KAGAN, Sarah A.; Banner & Witcoff, LTD., 1100 13th Street NW, Suite 1200, Washington, District of Columbia 20005-4051 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITION AND USE OF ENGINEERED MONOCLONAL ANTIBODIES REFRACTORY TO TUMOR IMMUNO-SUPPRESSIVE FACTORS

Fig 6A



(57) Abstract: The CA125/MUC16 protein has been found to be a suppressor of humoral immunity, in particular, antibody-mediated humoral immunity mediated through the direct binding to a subset of antibodies. Antibody variants can be generated that have reduced or eliminated CA125 binding yet retain the antigen specificity of the parental antibody. These can be used in treating patients with elevated CA125. CA 125-refractory antibodies are developed and used for treatment. Additionally, proteins that enhance humoral immunity in the presence of CA125 can be used to counter the suppression of humoral immunity.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*